2 results
Approved WMOCompleted
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…
Approved WMOCompleted
Primary: • To analyze the stability of the MHP using R.S.A to predict the long term survival.Secondary• To analyze the short term (1 year) safety of the MHP compared to the Stanmore hip replacement.• To analyze the short term (1 year) efficacy of…